12/11/2018 4:05:32 PM
Tenax Therapeutics Closes $10 Mln Underwritten Offering
8/28/2018 8:36:02 AM
Tenax Therapeutics: Clinical Study Results Say Levosimendan Offers Renal Protective Benefits To Heart Failure Patients
6/5/2018 4:36:56 PM
Tenax Therapeutics Appoints Anthony DiTonno As CEO
6/1/2018 8:37:54 AM
Tenax Therapeutics Reports Study Design For Phase 2 Trial Of Levosimendan In PH-HFpEF Patients
4/4/2018 8:05:44 AM
Tenax Therapeutics Announces Results Of Pre-IND Meeting With FDA For Phase 2 Study Of Levosimendan In PH-HFpEF Patients
3/14/2018 8:03:41 AM
Tenax Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
3/1/2018 8:46:16 AM
Tenax Announces Publication Of A Positive Preclinical Study Of Levosimendan Conducted By Hansen Et Al